Abstract：
UNASSIGNED: Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.
UNASSIGNED: This study compared the cost per response (CPR) for US patients initiating deucravacitinib versus apremilast for moderate to severe plaque psoriasis.
UNASSIGNED: A CPR model using pharmacy and administration costs was developed from a US payer perspective. Response was defined as a 75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at weeks 16 and 24. Long-term response was defined as the cumulative benefit over 52 weeks, measured as area under the curve; subsequent treatment was included. Scenario analyses explored varying the efficacy measure or choices of subsequent treatments and limiting discontinuation.
UNASSIGNED: The CPR for deucravacitinib versus apremilast was lower at 16 weeks (difference: -$3796 [95% confidence interval (CI): -$6140 to -$1659]) and 24 weeks (difference: -$12,784 [95% CI: -$16,674 to -$9369]). At 52 weeks, the cost per cumulative benefit was lower for patients who initiated deucravacitinib, regardless of initial treatment period duration (16 or 24 weeks).
UNASSIGNED: Scenario analyses found mainly consistent results. This study showed that the CPR is lower when initiating deucravacitinib versus apremilast in moderate to severe plaque psoriasis.
UNASSIGNED: This study compared the cost per response (CPR) for US patients initiating deucravacitinib versus apremilast for moderate to severe plaque psoriasis.
UNASSIGNED: A CPR model using pharmacy and administration costs was developed from a US payer perspective. Response was defined as a 75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at weeks 16 and 24. Long-term response was defined as the cumulative benefit over 52 weeks, measured as area under the curve; subsequent treatment was included. Scenario analyses explored varying the efficacy measure or choices of subsequent treatments and limiting discontinuation.
UNASSIGNED: The CPR for deucravacitinib versus apremilast was lower at 16 weeks (difference: -$3796 [95% confidence interval (CI): -$6140 to -$1659]) and 24 weeks (difference: -$12,784 [95% CI: -$16,674 to -$9369]). At 52 weeks, the cost per cumulative benefit was lower for patients who initiated deucravacitinib, regardless of initial treatment period duration (16 or 24 weeks).
UNASSIGNED: Scenario analyses found mainly consistent results. This study showed that the CPR is lower when initiating deucravacitinib versus apremilast in moderate to severe plaque psoriasis.
摘要：
■了解deucravitinib和apremilast的经济价值可以帮助中度至重度斑块状银屑病患者的治疗决策。
■本研究比较了美国患者开始使用ducravitinib和apremilast治疗中度至重度斑块状银屑病的每反应成本（CPR）。
■从美国付款人的角度开发了一种使用药房和管理成本的CPR模型。反应定义为在第16周和第24周时银屑病面积和严重程度指数(PASI75)从基线减少75%。长期反应被定义为超过52周的累积益处。以曲线下面积测量；包括后续治疗。情景分析探讨了改变后续治疗的疗效测量或选择以及限制停药。
■在16周（差异：-$3796[95％置信区间（CI）：-$6140至-$1659]）和24周（差异：-$12,784[95％CI：-$16,674至-$9369]）时，deucravitinib的CPR较低。52周时,对于开始使用ducravitinib的患者，其累积获益成本较低，无论初始治疗期持续时间（16或24周）。
情景分析发现结果基本一致。这项研究表明，在中度至重度斑块型银屑病中，开始使用deucravitinib时的CPR低于apremilast。
■本研究比较了美国患者开始使用ducravitinib和apremilast治疗中度至重度斑块状银屑病的每反应成本（CPR）。
■从美国付款人的角度开发了一种使用药房和管理成本的CPR模型。反应定义为在第16周和第24周时银屑病面积和严重程度指数(PASI75)从基线减少75%。长期反应被定义为超过52周的累积益处。以曲线下面积测量；包括后续治疗。情景分析探讨了改变后续治疗的疗效测量或选择以及限制停药。
■在16周（差异：-$3796[95％置信区间（CI）：-$6140至-$1659]）和24周（差异：-$12,784[95％CI：-$16,674至-$9369]）时，deucravitinib的CPR较低。52周时,对于开始使用ducravitinib的患者，其累积获益成本较低，无论初始治疗期持续时间（16或24周）。
情景分析发现结果基本一致。这项研究表明，在中度至重度斑块型银屑病中，开始使用deucravitinib时的CPR低于apremilast。
